Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.
about
Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) geneComputational systems analysis of dopamine metabolismVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryVesicular monoamine transporter 2: role as a novel target for drug developmentEdaravone guards dopamine neurons in a rotenone model for Parkinson's diseaseExperimenting with spirituality: analyzing The God Gene in a nonmajors laboratory courseIdentification of a gastrin response element in the vesicular monoamine transporter type 2 promoter and requirement of 20 S proteasome subunits for transcriptional activityVesicular integrity in Parkinson's diseaseThe Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivoVMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Rho GTPase regulation of α-synuclein and VMAT2: implications for pathogenesis of Parkinson's diseaseBrain serotonergic circuitriesAssociations among types of impulsivity, substance use problems and neurexin-3 polymorphisms.VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.Monoamine transporters: vulnerable and vital doorkeepers.Animal models of the non-motor features of Parkinson's disease.Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synucleinReduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degenerationAnalysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.Drosophila modifier screens to identify novel neuropsychiatric drugs including aminergic agents for the possible treatment of Parkinson's disease and depressionIn vivo beta-cell imaging with VMAT 2 ligands--current state-of-the-art and future perspective.PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.hVMAT2: A Target of Individualized Medication for Parkinson's Disease.Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson׳s disease.Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals.N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.Pharmacological therapy in Parkinson's disease: focus on neuroprotection.Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease.DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.Identification of potential drugs for Parkinson's disease based on a sub-pathway method.Zingerone activates VMAT2 during MPP(+) -induced Cell Death.
P2860
Q21091188-13B0A92A-F4E1-4EBB-94EE-D0CBDC6FDD98Q21144295-FC682095-601D-4DEE-9DBA-8C76ABBC98C1Q24601233-D4EE3342-B4DF-4AD7-9307-79A57206C193Q24647764-0D144015-0A5B-4C89-85EC-9D7C4189F5F3Q27335848-BA6F5CD1-140A-4BA1-B748-D3B4B3F0FCA8Q28271336-00DD0EBE-EF26-4B03-8A3B-CA30264408B8Q28298413-C7CAB3C4-6C4B-4E40-9428-AA6ADBA87122Q28385737-FC7E9A1B-C132-4B2B-8A78-75969458119BQ30430534-FD8F90A3-B164-462A-BC12-C4D93D900D9CQ33724885-6B28B43D-D44F-499D-A46D-7AA9EF4EE32EQ33854736-05AA8AF0-662A-4B17-A4D5-B84799FED5D5Q33919434-82BE617B-5C9E-422D-A0C1-402E14E80D27Q33919548-2AF2B707-3B29-4C8E-85D3-3CFE347062A0Q34595165-83860B3A-9C1D-4CF4-B025-A9BDB70E6B20Q35184890-1A894C9D-EDF4-4C0F-8E34-92195741CCAEQ35237299-953F9CDF-A102-4428-A758-11136B44BBFFQ35661896-B17F0509-B0DC-41D0-B295-3454EF7ADF08Q35775723-467D72B3-22DF-48B6-93D5-19709F601572Q35877150-3C91077D-D177-431B-9A0A-9FB2D07F2951Q36235578-7DB02099-A7EC-412C-8E5A-3CE848F6F1E0Q36585297-40D37C75-26EC-44C1-82A2-2AB28CBE9491Q36691830-BEFC760F-F425-400D-A905-484C7312A760Q36708352-55DB0078-7B9C-411F-AE51-EF0F34569A61Q36724670-FC05A42A-3696-423A-B4EA-17D81E79F1FAQ36773604-2232B80C-94DD-4AE1-9119-9AFEEE987297Q36942673-C2EBCB29-C7DB-4067-B495-A72E651466E8Q37136467-CFD32DF8-1915-410B-B2B3-F652F16B453CQ37320854-F88D0A57-E104-459E-8528-9DE8AEC46454Q37381249-508F1A76-D1E8-46CF-9ECD-F8671AA2BDC2Q37589110-F7838006-5E39-4896-A734-EBB373BF72E2Q37711589-E670EC5A-CEF0-4B3E-B498-CFD0D91DD52CQ37741285-F527AB73-DCC3-4CA0-81DE-C53D393ADAFDQ38366271-175840F1-1410-43CE-9E25-3056DE6403A6Q38926644-90370038-A345-4CDC-8FDB-70CA6045B337Q39154570-8EF45BEB-4B40-42C6-A303-FE73DA8F2354Q39298707-8DE6E351-20C9-430F-9B58-5CA5DBAC8DC2Q41031814-BD19D8C9-A5B4-458C-9A3F-75FDBD98509DQ41927560-CF7069B8-81EA-42AF-97DE-64528D95E65CQ42703601-2425D2A1-1E2D-43D5-83E7-4B1012815D17Q46683287-C72E9080-364A-46BC-AE1A-671AE8D828E9
P2860
Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@ast
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@en
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@nl
type
label
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@ast
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@en
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@nl
prefLabel
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@ast
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@en
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@nl
P2093
P2860
P356
P1476
Gain-of-function haplotypes in ...... or Parkinson disease in women.
@en
P2093
Andres Ruiz-Linares
Angelika D Wahner
Charles E Glatt
Daniel J White
P2860
P304
P356
10.1093/HMG/DDI445
P50
P577
2005-12-08T00:00:00Z